Eventide Asset Management’s Recursion Pharmaceuticals RXRX Stock Holding History

Eventide Asset Management’s Portfolio RXRX Stock Details RXRX Fund Activity

Bought

Maintained

Sold

Quarter	Market Value	Status	Shares	Change in Stake	Trade Value	Portfolio Weight	Portfolio Position
2026 Q2	$87.6K	Buy	+23,752	New	+$79.1K	﹤0.01%	292

Other funds holding RXRX

BlackRock New York $6.73T AUM 46.02% 1-Year Est. Return

AIM

ARK Investment Management St. Petersburg, Florida $15.4B AUM 50.29% 1-Year Est. Return

State Street Boston, Massachusetts $3.37T AUM 44.26% 1-Year Est. Return

Vanguard Portfolio Management Malvern, Pennsylvania $2.22T AUM

Baillie Gifford & Co Edinburgh, United Kingdom $110B AUM 4.8% 1-Year Est. Return

Vanguard Capital Management Malvern, Pennsylvania $4.68T AUM

Geode Capital Management Boston, Massachusetts $1.88T AUM 44.46% 1-Year Est. Return

SoftBank Group Tokyo, Japan $18.2B AUM 177.65% 1-Year Est. Return

MCMU

MIC Capital Management (UK) London, United Kingdom $394M AUM 25.64% 1-Year Est. Return

UBS Group Zurich, Switzerland $786B AUM 40.34% 1-Year Est. Return

Eventide Asset Management's RXRX Position: Q2 2026 in Review

Eventide Asset Management opened a new position in Recursion Pharmaceuticals (RXRX) in Q2 2026: 23,752 shares worth $87.6K. The stake represents ﹤0.01% of the portfolio and ranks #292 among its holdings.

342 funds tracked by Wall St. Rank hold RXRX as of Q2 2026.

Eventide Asset Management held 23,752 shares of Recursion Pharmaceuticals worth $87.6K as of Q2 2026.
Recursion Pharmaceuticals was a new Eventide Asset Management position in Q2 2026.
Recursion Pharmaceuticals made up ﹤0.01% of Eventide Asset Management's portfolio in Q2 2026, its #292 holding.
342 funds tracked by Wall St. Rank held Recursion Pharmaceuticals as of Q2 2026.

Based on Eventide Asset Management's 13F filing for Q2 2026, filed 14 Aug 2026.